Predictive Value of a SNP Signature and Liquid Biopsy in Natural Killer T-cell Lymphoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04423536

Enrollment

800

Registered

2020-06-09

Start date

2021-03-09

Completion date

2025-03-31

Last updated

2022-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Natural Killer T-cell Lymphoma

Brief summary

The purpose of this study is to determine the Predictive value of a SNP signature and liquid biopsy in patients with natural killer T-cell lymphoma.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* biopsy proved Natural Killer T-cell Lymphoma * newly diagnosed patients

Exclusion criteria

* patients with biopsy samples unavailable

Design outcomes

Primary

Measure	Time frame
Overall survival	5-years

Countries

China

Contacts

Primary ContactQing qing Cai, MD

caiqq@sysucc.org.cn0086-20-87342823

Outcome results